| __timestamp | Amphastar Pharmaceuticals, Inc. | Corcept Therapeutics Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 34916000 |
| Thursday, January 1, 2015 | 46974000 | 36949000 |
| Friday, January 1, 2016 | 47298000 | 45240000 |
| Sunday, January 1, 2017 | 50918000 | 62416000 |
| Monday, January 1, 2018 | 58044000 | 81289000 |
| Tuesday, January 1, 2019 | 63109000 | 100359000 |
| Wednesday, January 1, 2020 | 65157000 | 105326000 |
| Friday, January 1, 2021 | 68920000 | 122356000 |
| Saturday, January 1, 2022 | 66592000 | 152848000 |
| Sunday, January 1, 2023 | 80393000 | 184259000 |
Unleashing the power of data
In the competitive world of biopharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Corcept Therapeutics Incorporated and Amphastar Pharmaceuticals, Inc. have shown distinct trends in their SG&A expenditures. From 2014 to 2023, Corcept's SG&A expenses surged by over 400%, reflecting its aggressive growth strategy and expansion efforts. In contrast, Amphastar's expenses grew by approximately 100%, indicating a more conservative approach.
By 2023, Corcept's SG&A expenses were nearly double those of Amphastar, highlighting its significant investment in administrative and sales functions. This divergence in financial strategy underscores the different paths these companies have taken in the biopharma landscape. As the industry continues to evolve, monitoring these expenses will be key to understanding each company's future trajectory.
Selling, General, and Administrative Costs: argenx SE vs Amphastar Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Biogen Inc. and Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Amphastar Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs Amphastar Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Incyte Corporation and Corcept Therapeutics Incorporated
Dr. Reddy's Laboratories Limited and Corcept Therapeutics Incorporated: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Alkermes plc
Corcept Therapeutics Incorporated and Perrigo Company plc: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs MorphoSys AG Trends and Insights
SG&A Efficiency Analysis: Comparing Corcept Therapeutics Incorporated and Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.